GlycoScientific, LLC is a privately-held company engaged in the development and commercialization of unique research reagents in the field of glycobiology, including development of products that involve characterization of glycosylation. The company is based in Athens, Georgia, next door to the University of Georgia’s Complex Carbohydrate Research Center. The company is backed by a team that is embedded in many relevant disciplines, including proteomics, glycomics, liquid chromatography and mass spectrometry of glycans and glycoproteins. GlycoScientific has received funding from the National Institutes of Health and private sources, including the Georgia Research Alliance.
Our lead product, iGlycoMabTM is a stable isotope labeled monoclonal antibody (mAb) designed for use as an internal standard to facilitate the accurate and precise quantitative glycan profiling of biological therapeutics, particularly monoclonal antibodies and fusion proteins. However, iGlycoMabTM can be applied to individual glycans or complex mixtures such as those observed in the field of glycomics.
We work intensively in the development of antibodies for quantitation of specific glycan modifications. We focus on modifications of proteins involved in serious human diseases, including cancer, diabetes and neurodegenerative disorders. We have a unique technology platform that overcomes hurdles in the development of glycoprotein specific antibodies. We will soon be making available a number of these antibodies for sale on our website. If you have a protein with a glycan or other modification for which you need an antibody, please contact us and we will see if our technology can fulfill your needs. We are always on a steep learning curve so please reach out to us with your ideas and comments.